Dudediligence.

REGENXBIO Inc

RGNXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$24.2MSep ’24$21.2MDec ’24$89.0MMar ’25$21.4MJun ’25$29.7MSep ’25$30.3MDec ’25$6.4MMar ’26$108.0MJun ’26
Net income, by quarter
−$59.6MSep ’24−$51.2MDec ’24$6.1MMar ’25−$70.9MJun ’25−$61.9MSep ’25−$67.1MDec ’25−$90.1MMar ’26$22.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$470.3M$112.7M$90.2M$83.3M$170.4M
Gross profit$418.5M$58.2M$53.0M$49.8Mnone on file
Operating income$160.0M−$262.9M−$268.1M−$233.3M−$161.2M
Net income$127.8M−$280.3M−$263.5M−$227.1M−$193.9M
Operating cash flow$218.9M−$207.5M−$218.4M−$173.1M−$124.0M
Free cash flow$134.7M−$238.2M−$228.4M−$175.6M−$126.4M
Cash$345.2M$97.0M$34.5M$57.5M$34.5M
Shares outstanding42.8M43.3M44.0M49.5M50.9M